Immuneering Corporation has appointed Grant Bogle, an experienced oncology commercial leader, to its Board of Directors. Bogle brings over 40 years of pharmaceutical expertise, including successful launches of cancer therapies like ZEJULA and leadership roles at TESARO, Epizyme, and Nuvalent. His appointment comes as Immuneering advances its lead cancer drug candidate, atebimetinib, through clinical trials targeting pancreatic and other cancers. Bogle's commercial and strategic experience is expected to support Immuneering’s efforts to prepare for regulatory approval and market launch, aiming to deliver new treatment options to patients.
Immuneering's board appointment news provides context for readers interested in health sector trends. As of Nov 09, 2026 18:41 WIB, 108 of 150 priced health-sector US stocks on Pluang rose while 26 fell. Notable movers include TG Therapeutics Inc at USD 63.00 with a 5.31% increase, Guardant Health Inc. at USD 157.76 up 4.57%, and ClearPoint Neuro Inc at USD 8.99 gaining 4.53%.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
